Skip to main content

Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

Publication ,  Journal Article
Kirk, AD; Harlan, DM
Published in: Nature Medicine
February 2000

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature Medicine

DOI

EISSN

1546-170X

ISSN

1078-8956

Publication Date

February 2000

Volume

6

Issue

2

Start / End Page

114 / 114

Publisher

Springer Science and Business Media LLC

Related Subject Headings

  • Immunology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kirk, A. D., & Harlan, D. M. (2000). Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine, 6(2), 114–114. https://doi.org/10.1038/72164
Kirk, Allan D., and David M. Harlan. “Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.” Nature Medicine 6, no. 2 (February 2000): 114–114. https://doi.org/10.1038/72164.
Kirk, Allan D., and David M. Harlan. “Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.” Nature Medicine, vol. 6, no. 2, Springer Science and Business Media LLC, Feb. 2000, pp. 114–114. Crossref, doi:10.1038/72164.
Kirk AD, Harlan DM. Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Medicine. Springer Science and Business Media LLC; 2000 Feb;6(2):114–114.

Published In

Nature Medicine

DOI

EISSN

1546-170X

ISSN

1078-8956

Publication Date

February 2000

Volume

6

Issue

2

Start / End Page

114 / 114

Publisher

Springer Science and Business Media LLC

Related Subject Headings

  • Immunology
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences